Zachariah McIver - 01 Jan 2025 Form 3 Insider Report for Janux Therapeutics, Inc. (JANX)

Role
Chief Medical Officer
Signature
/s/ James Pennington, Attorney-in-Fact
Issuer symbol
JANX
Transactions as of
01 Jan 2025
Net transactions value
$0
Form type
3
Filing time
03 Jan 2025, 20:00:11 UTC
Next filing
03 Jan 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding JANX Stock option (right to buy) 01 Jan 2025 Common Stock 62,500 $12.10 Direct F1
holding JANX Stock option (right to buy) 01 Jan 2025 Common Stock 83,700 $11.02 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the option vested on June 1, 2024 and the balance of the shares vest in equal monthly installments thereafter over a three year period.
F2 25% of the shares subject to the option vest on January 1, 2025 and the balance of the shares vest in equal monthly installments thereafter over a three year period.